Enhancement in line of therapy (LoT) derivation from real-world data (RWD) from electronic health records (EHR) via integration of medical claims data.

Authors

null

Smita Agrawal

ConcertAI, Bengaluru, Karnataka, India

Smita Agrawal , Avinash P B , Rohini George , Neeraj Singh , Megha Soni , Sangavai Chakkrapani , Vandana Priya , Vivek Prabhakar Vaidya

Organizations

ConcertAI, Bengaluru, Karnataka, India

Research Funding

No funding received
None.

Background: Clinical RWD derived from EHRs is becoming increasingly important for clinical research, trial design, regulatory decisions etc. These applications require identification of lines of therapy (LoT) which are typically not captured in EHR and must be abstracted from other clinical and medication data. EHR data has significant missingness which can be complemented with other data sources such as medical claims data. In this study, we demonstrate how our proprietary line of therapy algorithms for solid cancers show significant improvements when built using integrated EHR and claims data when compared to EHR data alone. Methods: For this analysis, ConcertAI’s RWD360 dataset integrated with a large administrative open-claims dataset (>90% overlap) for 14 solid cancer indications (Breast, Bladder, Lung, Prostate, Pancreas, Melanoma, Liver, Head & Neck, Renal, Colorectal, Melanoma, Ovarian, Thyroid, Endometrial) was used. The date of advanced/metastatic diagnosis used as the index date for LoTs was derived from the EHR data and medications from both EHR and claims data were used. We ran our LoT algorithms on EHR data with and without claims data and evaluated the impact of integrating claims data on the quantity and quality of LoT output. Results: The inclusion of medication data from claims significantly increased (7-22%) the number of patients for which LoTs could be extracted from the EHR data. Furthermore, we observed increases in number of lines per patient, length of lines and medications per line across cohorts. The distance between index date and 1st line start date was shortened in a subset (2-12%) of patients as a result. In a small fraction of cases, we even observed removal of false lines as some of the lines moved to adjuvant/neoadjuvant setting by filling in missing medication from claims. Overall, 7-39% patients in the LoT cohorts were impacted by addition of claims. Results for a few cancer types are presented in Table 1. We also compared the top LoTs derived from the integrated dataset against the standard of care for that cancer and observed very good concordance. Conclusions: Deriving LoTs by integrating data from multiple data sources such as EHR and claims can significantly improve its accuracy.

Impact analysis of claims integration on LoTs for 5/14 solid cancer cohorts.

Cancer Indication Breast Lung Prostate Pancreas Renal
# Pts with LoTs before claims integration 49826 53961 24309 12584 6639
# Pts with LoTs post claims integration 54557 57806 27191 13631 7478
# Pts added due to addition of claims 5034 3960 3019 1066 866
# False positive pts removed due to claims integration 303 115 137 19 27
# Pts with enhanced LoTs 18104 5421 9417 1461 1733
# Pts with decrease in days between index date and LoT start date 3680 1318 3018 308 442
# Total pts impacted 23441 (47.1%) 9381 (17.6%) 12436 (51.7%) 2527 (20.2%) 2626 (39.5%)

Pts, patients.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Health Services Research and Quality Improvement

Track

Quality Care/Health Services Research

Sub Track

Real-World Data/Outcomes

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 6514)

DOI

10.1200/JCO.2023.41.16_suppl.6514

Abstract #

6514

Poster Bd #

6

Abstract Disclosures

Similar Abstracts

First Author: Jihong Zong

Abstract

2024 ASCO Gastrointestinal Cancers Symposium

Phase 1/2 evaluation of revumenib in patients with advanced colorectal cancer and other solid tumors.

First Author: Aparna Raj Parikh